Anixa Biosciences (ANIX) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

ANIX · Stock Price

USD 2.96+0.31 (+11.70%)

Market Cap: $99.2M

Historical price data

Market Cap: $99.2MPipeline: 2 drugsFounded: 1989HQ: San Jose, United States

Sector Ranking#62 in Cell & Gene Therapy #119 in Oncology (General)

Overview

Anixa Biosciences is a clinical-stage biotech focused on transforming oncology through its innovative 'retired protein' antigen platform, which aims to deliver tumor-specific immunotherapies with improved safety profiles. The company's two core technologies are a novel CER-T (Chimeric Endocrine Receptor T-cell) therapy for ovarian cancer and a vaccine platform targeting triple-negative breast cancer (TNBC) and ovarian cancer for both treatment and prevention. Recent milestones include advancing its breast cancer vaccine toward Phase 2 and presenting early clinical data for its ovarian cancer CAR-T therapy. Anixa's strategy targets significant unmet needs in solid tumors by aiming to overcome the on-target, off-tumor toxicity that has limited broader application of current immunotherapies.

OncologyCancer

Technology Platform

A dual-platform approach targeting 'retired proteins': 1) Chimeric Endocrine Receptor T-cell (CER-T) therapy, a novel CAR-T variant for solid tumors, and 2) A vaccine platform for immunizing against retired tissue-specific proteins to treat and prevent cancer.

Pipeline

2

2 drugs in pipeline

Drug	Indication	Stage	Watch
Follicle Stimulating Hormone Receptor T Cells	Ovarian Cancer	Phase 1
α-lactalbumin vaccine + Zymosan	Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer	Phase 1

Opportunities

Anixa's retired protein platform addresses a core challenge in solid tumor immunotherapy—tumor-specific targeting—potentially unlocking safer and more effective treatments for cancers like TNBC and ovarian cancer.

Success could lead to expansion into other high-incidence cancers (lung, colon, prostate) and pioneer a new class of prophylactic cancer vaccines.

Risk Factors

The company faces high clinical risk as its novel platforms are unproven in late-stage trials, significant financial/dilution risk as a pre-revenue micro-cap, and intense competition from larger, better-funded entities in both cell therapy and vaccine spaces.

Competitive Landscape

Anixa competes in the crowded solid-tumor CAR-T space, differentiated by its unique FSHR target (CER-T), and in cancer vaccines, differentiated by its off-the-shelf, retired protein approach. It faces competition from large biopharma and biotechs advancing personalized neoantigen vaccines and other cell therapy modalities.